164 related articles for article (PubMed ID: 35932387)
1. Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
Shimizu T; Nakajima TE; Yamamoto N; Yonemori K; Koyama T; Kondo S; Sunakawa Y; Izawa N; Horie Y; Xiang S; Xu S; Qin L; Gong J; Liu D
Invest New Drugs; 2022 Oct; 40(5):1021-1031. PubMed ID: 35932387
[TBL] [Abstract][Full Text] [Related]
2. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Harb W; Peer CJ; Hua Q; Xu S; Lu H; Lu N; He Y; Xu T; Dong R; Gong J; Liu D
Oncologist; 2021 Sep; 26(9):e1514-e1525. PubMed ID: 33973293
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
[TBL] [Abstract][Full Text] [Related]
4. [A phase I study of subcutaneous envafolimab (KN035) monotherapy in Chinese patients with advanced solid tumors].
Liu RR; Gu SZ; Zhou T; Lin LZ; Chen WC; Zhong DS; Liu TS; Yang N; Shen L; Xu SY; Lu N; Zhang Y; Gong ZL; Xu JM
Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):898-903. PubMed ID: 37875426
[No Abstract] [Full Text] [Related]
5. Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors.
Chen M; Jiang M; Wang X; Shen L; Li J
Expert Opin Biol Ther; 2022 Oct; 22(10):1227-1232. PubMed ID: 36124972
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
Johnson ML; Braiteh F; Grilley-Olson JE; Chou J; Davda J; Forgie A; Li R; Jacobs I; Kazazi F; Hu-Lieskovan S
JAMA Oncol; 2019 Jul; 5(7):999-1007. PubMed ID: 31145415
[TBL] [Abstract][Full Text] [Related]
7. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
Felip E; Moreno V; Morgensztern D; Curigliano G; Rutkowski P; Trigo JM; Calvo A; Kowalski D; Cortinovis D; Plummer R; Maio M; Ascierto PA; Vladimirov VI; Cervantes A; Zudaire E; Hazra A; T'jollyn H; Bandyopadhyay N; Greger JG; Attiyeh E; Xie H; Calvo E
Cancer Chemother Pharmacol; 2022 Apr; 89(4):499-514. PubMed ID: 35298698
[TBL] [Abstract][Full Text] [Related]
8. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
[TBL] [Abstract][Full Text] [Related]
9. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
Naing A; Gainor JF; Gelderblom H; Forde PM; Butler MO; Lin CC; Sharma S; Ochoa de Olza M; Varga A; Taylor M; Schellens JHM; Wu H; Sun H; Silva AP; Faris J; Mataraza J; Cameron S; Bauer TM
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179633
[TBL] [Abstract][Full Text] [Related]
10. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
[TBL] [Abstract][Full Text] [Related]
11. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
[TBL] [Abstract][Full Text] [Related]
12. First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
Leidner R; Conlon K; McNeel DG; Wang-Gillam A; Gupta S; Wesolowski R; Chaudhari M; Hassounah N; Lee JB; Ho Lee L; O'Keeffe JA; Lewis N; Pavlakis GN; Thompson JA
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37907221
[TBL] [Abstract][Full Text] [Related]
13. Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis.
Zhang Y; Chen Z; Liu Y; Han L; Jiang W; Wang Q; Shi J; Lu L; Li J; Zhang M; Huang Y; Yang Y; Hou X; Zhang L; Li J; Fang W; Chen G
Cancer Med; 2024 Apr; 13(7):e7175. PubMed ID: 38597130
[TBL] [Abstract][Full Text] [Related]
14. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
[TBL] [Abstract][Full Text] [Related]
15. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
Zhang Q; Zhang J; Zhong H; Yuan Y; Yang L; Zhang Q; Ji D; Gong J; Li J; Yao Z; Qi C; Wang J; Lu L; Shi M; Qian X; Shen L; Li J; Hu X
Cancer Immunol Immunother; 2023 Aug; 72(8):2729-2739. PubMed ID: 37115210
[TBL] [Abstract][Full Text] [Related]
17. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
Liu D; Zhou J; Wang Y; Li M; Jiang H; Liu Y; Yin X; Ge M; Xiang X; Ying J; Huang J; Zhang YQ; Cheng Y; Huang Z; Yuan X; Han W; Yan D; Wang X; Liu P; Wang L; Zhang X; Luo S; Liu T; Shen L
BMC Med; 2022 Oct; 20(1):408. PubMed ID: 36280870
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.
Liu D; Ma C; Lu P; Gong J; Ye D; Wang S; Peng P; Bai Y; Song Y; Chen J; Jiang O; Zhang G; Ba Y; Chen L; Pan J; Li Q; Zhang L; Gu S; Yin X; Cao B; Han W; Dong H; Guo J; Zhang H; Su H; Jiang Y; Ouyang W; Ma L; Sun Y; Zhang F; Lv J; Guo Y; Xu C; Qi J; Wang L; Wang X; Liu Z; Shen L
Eur J Cancer; 2021 May; 148():1-13. PubMed ID: 33691262
[TBL] [Abstract][Full Text] [Related]
19. Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.
Fujiwara Y; Takahashi Y; Okada M; Kishimoto T; Kondo S; Fujikawa K; Hayama M; Sugeno M; Ueda S; Komuro K; Lanasa M; Nakano T
Oncologist; 2022 Sep; 27(9):e703-e722. PubMed ID: 35671201
[TBL] [Abstract][Full Text] [Related]
20. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]